Physostigmine Salicylate Articles
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
Pfizer gets US FDA approval for Prevnar 13, a Wyeth drug with blockbuster sales outlook
25 February 2010
Amylin and partner Takeda move obesity drug candidate into Ph III
25 February 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Denmark’s Novo Nordisk debuts Victoza in the USA, aiming for $1 billion global sales by 2015
17 February 2010
UK’s NICE backs use of Novo Nordisk’s Victoza for diabetes, but only as triple therapy
15 February 2010
Shire presents strong Ph III velaglucerase alfa data in Type 1 Gaucher disease and Genzyme Ph II with eliglustat at LDN meeting
12 February 2010
Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations
10 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
3SBio licenses rights to Panacor Nephoxil for China
9 February 2010
UK/Czech scientists shed light on insulin activity
9 February 2010
European approval for Merck & Co’s Elonva and new indication for Roche’s Herceptin; Roche sets up Singapore research hub
28 January 2010
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
FDA approves Novo Nordisk’s new type 2 diabetes drug Victoza
26 January 2010
China Sky One Medical’s Tianlong subsidiary to focus R&D efforts on antibiotics and cardiac drugs
22 January 2010
Genzyme manufacturing woes hit sales; Amgen forecasts lower-end of expectations EPS and signs deal with MedGenisis
13 January 2010
European Commission OKs new IV form of Pfizer’s Revatio for pulmonary arterial hypertension
6 January 2010
Eli Lilly gets bonus with FDA’s Zyprexa Relprew approval
4 January 2010
Myriad to acquire Javelin in stock deal valued at $96 million
21 December 2009
Scottish Medical Consortium backs use of Novo Nordisk’s Victoza for type 2 diabetics
9 December 2009
Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn
8 December 2009
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
Pfizer to pay Protalix up to $115 million in Gaucher's disease treatment deal; Genzyme’s Cerezyme supply
2 December 2009
More bad news for Genzyme as US FDA delays Lumizyme application
17 November 2009
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Teva files suit against Momenta/Sandoz over Copaxone, OK for generic Prevacid in USA for Teva and Mylan
11 November 2009
Italy’s Sigma-Tau to takeover Enzon business for some $327 million in cash plus royalties
10 November 2009
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
EU approves Novartis’ Ilaris for CAPS; AstraZeneca withdraws Zactima marketing applications
28 October 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Spectrum plunges on FDA letter delaying Fusilev approval in advanced metastatic colorectal cancer
12 October 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
Allergan takes legal action against US govt over right to share info with physicians on Botox
5 October 2009
$20 Million drug plant opens in Mukono, Uganda
1 October 2009
GSK in 1.5 billion-euro deal with Brazil for pneumococcal vaccine; first Cervarix death reported
29 September 2009
Genzyme updates on Cerezyme and Fabrazyme sales now supply back on line
24 September 2009
Proposed new Therapeutic Goods Orders from Australia’s TGA
23 September 2009
Ipsen reveals positive findings with rhGH and Increlex
16 September 2009
Highlights of research presented at ICAAC
15 September 2009
Lilly plans to appeal over Gemzar's intellectual property
7 September 2009
J&J decision to halt risperidone inj a setback for Alkermes’ pipeline, say analysts
1 September 2009
AEterna Zentaris plunges as cetrorelix misses study endpoint
18 August 2009
BioSante’s BioVant gives 100% protection from H1N1 challenge
18 August 2009
Novartis Multiple sclerosis drug Extavia cleared by US FDA
17 August 2009
Genzyme’s Mozobil gains European Approval
6 August 2009
Immunomedics' veltuzumab shows 68% OR rate
8 June 2009
PVS-10200 increases lumen area in PAD
3 June 2009
Teikoku USA acquires Travanti Pharma
1 June 2009
Ferring present OA drug results at AAOS
19 May 2009
UCB teams with OXO to ease RA drug
18 May 2009
Xarelto more effective than enoxaparin in VTE
11 May 2009
Novo Nordisk
7 May 2009
Teva's 1st-qtr profit more than triples
6 May 2009
Exenatide once weekly NDA submitted to FDA
6 May 2009
Aoxing gets Chinese OK for angina drug
5 May 2009
Celgene swings back to profit in 1st qtr
5 May 2009
J&J/Alkermes' Risperdal Consta approved in Japan
30 April 2009
FDA appro for J&J arthritis drug Simponi
28 April 2009
Transgene's HCV vacc to enter Ph II in 2010
27 April 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Elan 1st-qtr net loss widens 20% to $102.6M
27 April 2009
Locteron shows better AE profile than PEG-Intron
24 April 2009
Phytopharm begins PD study with oral Cogane
24 April 2009
Alkermes completes Ph IIIb Vivitrol enrollment
22 April 2009
Sanofi invests $90M in Lantus plant in China
22 April 2009
Sanofi launches Apidra SoloSTAR in USA
21 April 2009
Strong Ph I data with Pantec's triptorelin patch
20 April 2009
Diabetes sales weaken with economy
20 April 2009
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
Amarillo supplies interferon for Australian flu study
16 April 2009
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
